Results 171 to 180 of about 113,823 (359)

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A [PDF]

, 2014
Atsushi Muto, Kazutaka Yoshihashi, Minako Takeda, Takehisa Kitazawa, Tetsuhiro Soeda, Tomoyuki Igawa, Zenjiro Sampei, Taichi Kuramochi, Akihisa Sakamoto, Kenta Haraya, Kenji Adachi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Kunihiro Hattori   +14 more
openalex   +1 more source

Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Coagulation testing in haemophilia A is limited by the scarcity of testing facilities capable of performing relevant assays. This issue incentivized the development of the EnzySystem for haemophilia A, a near‐patient testing platform aimed to measure Factor VIII activity and thrombin generation simultaneously within 1 h from 100 ...
Aernoud P. Bavinck, Kyle Davis, Lisa van Engelshoven, Monique G. van Lier, Tanja Hamacher, Nicole M. A. Blijlevens, Amy Shapiro, Saskia E. M. Schols, Waander L. van Heerde   +8 more
wiley   +1 more source

Strengthening hemophilia registries globally: Strategies to improve patient outcomes

Iraqi Journal of Hematology
Hemophilia is a genetic bleeding disorder characterized by a deficiency of clotting factor VIII or IX. Hemophilia registries are structured databases that maintain longitudinal data on people diagnosed with hemophilia. Hemophilia registries maintained at
Saurabh RamBihariLal Shrivastava, Prateek Sudhakar Bobhate, Shweta Sonkusale, Neha Jaiswal   +3 more
doaj   +1 more source

Impact of mild to severe hemophilia on education and work by US men, women, and caregivers of children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B‐HERO‐S) study [PDF]

, 2017
Susan Cutter, Don Molter, Spencer Dunn, Susan S. Hunter, Skye Peltier, Kimberly Haugstad, Neil Frick, Natalia Holot, David L. Cooper   +8 more
openalex   +1 more source

Five‐Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research

Haemophilia, EarlyView.
ABSTRACT Introduction To enhance the treatment quality in haemophilia centres (HC), the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research (GTH) started in 2017 the development of guidelines to define the structural and process quality of HC, essentially related to the EUHANET guidelines.
Hermann Eichler, Hagen Bönigk, Susan Halimeh, Christina Hart, Judith Hörner, Robert Klamroth, Ralf Knöfler, Christoph Königs, Thomas Lang, Florian Langer, Wolfgang Miesbach, Johannes Oldenburg, Ramona Oral, Martin Olivieri, Christian Pfrepper, Jan Pilch, Ute Scholz, Werner Streif, Manuela Albisetti   +18 more
wiley   +1 more source

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

New England Journal of Medicine, 2017
J. Oldenburg, J. Mahlangu, Benjamin Kim, C. Schmitt, M. Callaghan, G. Young, E. Santagostino, R. Kruse-Jarres, C. Négrier, C. Kessler, N. Valente, E. Asikanius, G. Levy, J. Windyga, M. Shima   +14 more
semanticscholar   +1 more source

Low‐Load Quadriceps Strengthening With Blood Flow Restriction in Adults With Haemophilic Knee Arthropathy: A Randomised Controlled Trial

Haemophilia, EarlyView.
Abstract Introduction Haemophilic knee arthropathy leads to a reduction in muscle mass and strength. Blood flow restriction (BFR) involves the application of a compressive cuff that enables strength training with reduced loads. Objective To evaluate safety as the primary outcome and the efficacy (muscle strength and activation, functional capacity and ...
Mar Villalón‐González, Raúl Pérez‐Llanes, José Antonio López‐Pina, Rubén Cuesta‐Barriuso, Elena Donoso‐Úbeda   +4 more
wiley   +1 more source

florio HAEMO—A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Despite therapeutic achievements in haemophilia care, there is still the need to monitor and define personal treatment outcomes and document results to achieve the best possible care. Hence, a need for unbiased, timely and comprehensive real‐world information exists to support informed shared decision‐making regarding treatment ...
Christoph Königs, Jan Astermark, Jan Blatny, Jamie O´Hara, Allfonso Iorio, Claude Negrier, Flora Peyvandi, Katharina Steinitz, Armin J. Reininger, Santiago Bonanad   +9 more
wiley   +1 more source

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

Patient Preference and Adherence, 2015
Roberto Furlan,1 Sangeeta Krishnan,2 Jeffrey Vietri3 1Advanced Methods, Kantar Health, Epsom, Surrey, UK; 2Global Health Economics and Outcomes Research, Biogen, MA, USA; 3Health Outcomes, Kantar Health, Milan, Italy Introduction: New longer-acting ...
Furlan R, Krishnan S, Vietri J
doaj  

Prospects for the use of prolonged concentrates of blood clotting factor IX in the treatment of hemophilia B

, 2021
V. N. Konstantinova, T. A. Andreeva, A. V. Kim   +2 more
openalex   +1 more source